All In Biotech

Drug Trial Radar · NCT03794440

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

A Randomized, Open-label,Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. (ORIENT-32)

Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 595 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

595

Actual

Start

Feb 11, 2019

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Sponsor type
Industry
First posted
Jan 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • SintilimabDrug

    200mg IV d1, Q3W

  • IBI305Drug

    15mg/kg IV d1, Q3W

  • SorafenibDrug

    400mg PO BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: up to 24 months after randomization
  2. Progression-free survival (PFS)Time frame: up to 24 months after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.